Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;11(1):CNS83.
doi: 10.2217/cns-2021-0005. Epub 2022 Feb 10.

Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch

Affiliations

Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch

Orwa Aboud et al. CNS Oncol. .

Abstract

Background: To illustrate challenges of imaging interpretation in patients with oligodendroglioma seen at a referral center and evaluate interrater reliability. Methods: Two neuro-oncologists reviewed diagnostic preradiation MRIs of oligodendroglioma patients; interrater reliability was calculated with the kappa coefficient (k). A neuroradiologist measured presurgical apparent diffusion coefficient (ADC), if available. Results: Extensive enhancement was noted in four of 58 patients, k = 0.7; necrosis in seven of 58, k = 0.61; calcification in seven of 17, k = 1.0; diffusion restriction in two of 39 patients, k = 1.0 (all only in grade 3). ADC values with receiver operator characteristic analysis for area under the curve were 0.473, not significantly different from the null hypothesis (p = 0.14). Conclusions: Extensive enhancement, necrosis and calcification correlated with grade 3 oligodendroglioma in our sample. However, interrater variability is an important limitation when assessing radiographic features, supporting the need for standardization of imaging protocols and their interpretation.

Keywords: calcification; contrast enhancement; examiner concordance; interrater reliability; necrosis; oligodendroglioma; restricted diffusion.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors are members of The NCI Comprehensive Oncology Network for Evaluating Rare CNS Tumors (NCI-CONNECT), which is a program within the Rare Tumor Patient Engagement Network (RTPEN), an initiative supported by the Cancer Moonshot funds and managed at the National Institutes of Health, National Cancer Institute, Center for Cancer Research, Neuro-Oncology Branch. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Diagram showing patients’ histology and extent of surgery.
Bx: Biopsy; GTR: Gross total resection; IDHm: IDH mutant: STR: Subtotal resection.
Figure 2.
Figure 2.. Representative images from a patient with oligodendroglioma WHO grade 2 (A–D).
MRI axial T1 with contrast, axial fluid-attenuated inversion recovery (FLAIR), and axial apparent diffusion coefficient (ADC) ([A], [B] and [C], respectively), showing a large left frontal mass with no obvious contrast enhancement, FLAIR hyperintensity and high ADC values. (D) Axial CT head without contrast showing left frontal hypodensity without definitive calcification.
Figure 3.
Figure 3.. Representative images from a patient with oligodendroglioma WHO grade 3 (A–D).
MRI Axial T1 with contrast, axial fluid-attenuated inversion recovery (FLAIR), and axial apparent diffusion coefficient (ADC) ([A], [B] and [C], respectively) showing right frontotemporal mass with contrast enhancement, FLAIR hyperintensity, and mixture of low and high ADC values. (D) Axial CT scan head without contrast showing right frontal calcification (single arrow) and bi-frontal intracranial hemorrhage (double arrow).

References

    1. Ostrom QT, Cioffi G, Gittleman H et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro. Oncol. 21(Suppl. 5), v1–v100 (2019). - PMC - PubMed
    1. Penas-Prado M, Wu J, Cahill DP et al. Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop. Neuro-Oncol. Advances. 2(1), vdz048 (2019). - PMC - PubMed
    2. • This article discusses challenges in oligodendroglioma treatment and future directions.

    1. Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta. Neuropathol. 131(6), 803–20 (2016). - PubMed
    1. Louis DN, Perry A, Wesseling P et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro. Oncol. 23(8), 1231–51 (2021). - PMC - PubMed
    2. • This article is important in defining oligodenroglioma and differentiating it from other rare diseases.

    1. Aoki K, Nakamura H, Suzuki H et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro. Oncol. 20(1), 66–77 (2018). - PMC - PubMed

MeSH terms